Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Arrowhead Pharmaceuticals Inc’s stock clocked out at $16.74, up 0.78% from its previous closing price of $16.61. In other words, the price has increased by $0.78 from its previous closing price. On the day, 1.5 million shares were traded.
Ratios:
To gain a deeper understanding of ARWR’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 502.57. For the most recent quarter (mrq), Quick Ratio is recorded 5.15 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 1.08 whereas as Long-Term Debt/Eq ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 11 ’25 when Anzalone Christopher Richard sold 50,800 shares for $11.49 per share. The transaction valued at 583,692 led to the insider holds 3,921,255 shares of the business.
Anzalone Christopher Richard sold 50,000 shares of ARWR for $543,500 on Apr 10 ’25. The Chief Executive Officer now owns 3,972,055 shares after completing the transaction at $10.87 per share. On Apr 09 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 40,322 shares for $10.07 each. As a result, the insider received 406,145 and left with 4,022,055 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.24 while its Price-to-Book (P/B) ratio in mrq is 3.38.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $30.41, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 22.04%, while the 200-Day Moving Average is calculated to be -9.76%.
Shares Statistics:
A total of 138.06M shares are outstanding, with a floating share count of 115.20M. Insiders hold about 16.58% of the company’s shares, while institutions hold 74.55% stake in the company.
